Conclusion of a significant purchase order
The Management Board of Selvita S.A. with its registered office in Krakow (“Issuer”, “Selvita”) hereby announces that on December 13, 2021 the
Issuer has received a purchase order with a total value of EUR 1.104.312,00 (PLN 5.127.983,20 converted at the rate EUR 1 = PLN 4,6436) under a framework agreement executed on June 20, 2018 between the Issuer and one of the largest pharmaceutical companies in the world with its registered office in Germany (“Client”). The Issuer’s business cooperation with the Client has begun in 2011, Selvita had reported expansion of its business relationship with the Client in the current stock report RB no 6/2020 dated March 30th, 2020.
The subject of the order is chemistry support in the FTE model in the Client’s R&D projects leading to the discovery of new drugs over the next 12 months.
Taking into account value of the purchase order, the Issuer’s Management Board considers the order to be significant for the implementation of Selvita Group’s long-term plans aiming at building a strong position on the international preclinical CRO (Clinical Research Organization) market.
Legal basis: Art. 17.1 of MAR
Representatives of the Company:
- Bogusław Sieczkowski – President of the Management Board
- Mirosława Zydroń – Management Board Member